GlaxoSmithKline announced the definitive agreement to acquire the oncology-focused biopharmaceutical company Tesaro for an aggregate cash value of approximately $5.1 billion. Tesaro’s major marketed product, Zejula (niraparib), is an oral poly-ADP ribose polymerase (PARP) inhibitor currently approved for use in ovarian cancer. Clinical trials are ongoing to assess its use in “all-comers” patient populations, as a monotherapy and in combinations; it is currently under investigation also as a possible treatment in lung, breast and prostate cancer. Tesaro’s pipeline includes also antibodies directed against PD-1, TIM-3 and LAG-3 targets.